Sciele Pharma, Inc., a Shionogi company, is a pharmaceutical company specializing in sales, marketing and development of branded prescription products focused on Cardiovascular/Diabetes, Women's Health and Pediatrics. The Company's Cardiovascular/Diabetes products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina and type 2 diabetes; its Women's Health products are designed to improve the health and well-being of women and mothers and their babies; and its Pediatrics products treat allergies, asthma, and attention deficit/hyperactivity disorder (ADHD).

Founded in 1992 and headquartered in Atlanta, Georgia, Sciele Pharma employs more than 1000 people. The company's success is based on placing the needs of patients first, improving health and quality of life, and implementing its business platform - an Entrepreneurial Spirit, Innovation, Speed of Execution, Simplicity, and Teamwork.

On October 9, 2008, Shionogi & Co., Ltd. ("Shionogi") and Sciele announced the completion of Shionogi's acquisition of Sciele. Sciele is now an indirect wholly owned subsidiary of Shionogi.

Shionogi & Co., LTD. Homepage

Sciele Pharma Announces Availability of Ulesfia (Benzyl Alcohol Lotion 5%), First Prescription Non-neurotoxic Head Lice Treatment

Sciele's Darrell Borne recieves 2009 CFO of the year award (Atlanta Business Chronicle)

Sciele Pharma Acquires Global Rights for PSD502 from Plethora Solutions

Sciele Pharma, a Shionogi company, to acquire Victory Pharma, Inc., a U.S. specialty pharmaceutical company

SCIELE PHARMA AND PLETHORA SOLUTIONS ANNOUNCE THAT PSD502 DEMONSTRATES SUBSTANTIAL BENEFIT IN THE TREATMENT OF PREMATURE EJACULATION